Impact Factor 4.259 | CiteScore 4.30
More on impact ›

Correction ARTICLE

Front. Microbiol., 01 October 2019 | https://doi.org/10.3389/fmicb.2019.02275

Corrigendum: Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics

Martti Vaara1,2*
  • 1Northern Antibiotics Ltd., Espoo, Finland
  • 2Department of Bacteriology and Immunology, Helsinki University Medical School, Helsinki, Finland

A Corrigendum on
Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics

by Vaara M. (2019). Front. Microbiol. 10:1689. doi: 10.3389/fmicb.2019.01689

In the original article, there was a mistake in Table 1 as published. The structure of SPR206 was partially incorrect. In the correct structure, R(FA) is (3S)-4-amino-3-(3-chlorophenyl)butanoyl, R1 is absent, and R3 is Dap+. The corrected Table 1 appears below.

TABLE 1
www.frontiersin.org

Table 1. The structures of polymyxin B, colistin, and the novel polymyxin derivatives that display improved efficacy in animal infection models (compounds 4-10)a,b.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: polymyxin B, colistin, extremely resistant (XDR), Gram-negative bacteria, improved polymyxins

Citation: Vaara M (2019) Corrigendum: Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics. Front. Microbiol. 10:2275. doi: 10.3389/fmicb.2019.02275

Received: 06 August 2019; Accepted: 18 September 2019;
Published: 01 October 2019.

Edited and reviewed by: Aixin Yan, The University of Hong Kong, Hong Kong

Copyright © 2019 Vaara. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Martti Vaara, martti.vaara@northernantibiotics.com

ORCID: Martti Vaara orcid.org/0000-0002-7971-0560